HKSE:2877

China Shineway Pharmaceutical Group Limited · HKSE · Healthcare · HKD · FY for 2025

Figures on this page computed 2026-11-08 13:40 UTC

Last close

n/aHKD

Market data

5.0xP/E
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
HKD
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
30.3%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
31.1%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
7.4%Dividend yield
Source
computed
Taken on
2026-11-08
Reported in
HKD
- computed

6 of 6 traits placed on the market's range. Nothing sits below its sector's middle.

All from 100

lens 2 of 9

Sales

157

2016-12-31 to 2025-12-31100 at the start157

Sales: 100.00 on 2016-12-31 to 157.29 on 2025-12-31, up 57%.

Profit

161

2016-12-31 to 2025-12-31100 at the start161

Profit: 100.00 on 2016-12-31 to 161.23 on 2025-12-31, up 61%.

Shares in issue

91.3

2016-12-31 to 2025-12-31100 at the start91.3

Shares in issue: 100.00 on 2016-12-31 to 91.34 on 2025-12-31, down 9%.

Sales is at 157, Profit is at 161, Shares in issue is at 91, against 100 in 2016.

Sales is at 157, Profit is at 161, Shares in issue is at 91, against 100 in 2016.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2025

Sales, where the first year is 100157
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
Profit, where the first year is 100161
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
Shares in issue, where the first year is 10091
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY